Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (456)	3/11/2006 1:04:01 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 557

Selling shares at 39 cents, net tangible book value after the offering, 8 cents. Common stock to be outstanding after this Offering 98,485,855 shares does not include: "7,040,870 shares of common stock issuable upon exercise of options outstanding as of December 31, 2005, of which 4,320,432 shares are exercisable, under our 1992 Restated Stock Option Plan, our Stock Option Plan for Nonemployee Directors, our 1999 Stock Option Plan and our 2000 Genovo, Inc. Roll-over Stock Option Plan at a weighted average exercise price of $2.70 per share; and 2,993,541 shares available for grant as of December 31, 2005 under our stock option plans" ----------- Whew, that is a lot of shares. I last held Tgen in the fall of 2004, but let those shares go around $1.20--a rare good call of mine I think! Currently, my position in dpii is down 20% which looks like a pretty trivial move down agaist what I might have lost in tgen. That said, I sold my Lynx around the same time however, and I think I'd have done okay there had I held the Solexa. A wash overall I suppose. Going nowhere fast! Here begins my next 5000 posts ha ha.